Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 43 | 2021 | 2889 | 4.010 |
Why?
|
Informed Consent | 18 | 2019 | 266 | 2.790 |
Why?
|
Clinical Trials, Phase I as Topic | 16 | 2018 | 155 | 2.630 |
Why?
|
Decision Making | 15 | 2020 | 641 | 1.800 |
Why?
|
Medical Oncology | 12 | 2015 | 357 | 1.650 |
Why?
|
Genes, BRCA2 | 5 | 2012 | 160 | 1.630 |
Why?
|
Genes, BRCA1 | 5 | 2012 | 192 | 1.610 |
Why?
|
Truth Disclosure | 9 | 2012 | 87 | 1.470 |
Why?
|
Attitude of Health Personnel | 11 | 2014 | 636 | 1.400 |
Why?
|
Pharmaceutical Preparations | 2 | 2020 | 92 | 1.290 |
Why?
|
Disclosure | 8 | 2018 | 108 | 1.210 |
Why?
|
Clinical Trials as Topic | 8 | 2019 | 1168 | 1.090 |
Why?
|
Comprehension | 8 | 2018 | 79 | 1.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 5 | 2020 | 508 | 1.050 |
Why?
|
Practice Patterns, Physicians' | 7 | 2014 | 578 | 1.010 |
Why?
|
Patient Participation | 8 | 2016 | 216 | 0.980 |
Why?
|
Research Subjects | 10 | 2014 | 73 | 0.950 |
Why?
|
Patients | 4 | 2007 | 100 | 0.940 |
Why?
|
Pharmacists | 2 | 2020 | 32 | 0.880 |
Why?
|
Physicians | 4 | 2020 | 672 | 0.860 |
Why?
|
Patient Preference | 2 | 2020 | 104 | 0.830 |
Why?
|
Survivors | 6 | 2016 | 225 | 0.790 |
Why?
|
Attitude to Health | 4 | 2007 | 220 | 0.790 |
Why?
|
Parent-Child Relations | 3 | 2012 | 77 | 0.780 |
Why?
|
Ethics, Medical | 8 | 2008 | 306 | 0.770 |
Why?
|
Genetic Testing | 3 | 2010 | 535 | 0.770 |
Why?
|
Prognosis | 15 | 2018 | 3669 | 0.750 |
Why?
|
Caregivers | 2 | 2021 | 151 | 0.750 |
Why?
|
Pharmacy Service, Hospital | 1 | 2019 | 9 | 0.700 |
Why?
|
Pharmacy | 1 | 2019 | 7 | 0.700 |
Why?
|
Hospice Care | 3 | 2004 | 39 | 0.670 |
Why?
|
Middle Aged | 44 | 2022 | 24957 | 0.670 |
Why?
|
Hematologic Neoplasms | 5 | 2018 | 329 | 0.670 |
Why?
|
Nontherapeutic Human Experimentation | 5 | 2000 | 20 | 0.660 |
Why?
|
Physician-Patient Relations | 6 | 2016 | 610 | 0.660 |
Why?
|
Health Care Rationing | 1 | 2019 | 83 | 0.660 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 173 | 0.660 |
Why?
|
Humans | 75 | 2023 | 86281 | 0.630 |
Why?
|
Research Personnel | 1 | 2018 | 67 | 0.630 |
Why?
|
Surveys and Questionnaires | 16 | 2019 | 2495 | 0.620 |
Why?
|
Adult | 42 | 2022 | 25577 | 0.610 |
Why?
|
Complementary Therapies | 2 | 2008 | 54 | 0.600 |
Why?
|
Referral and Consultation | 4 | 2009 | 326 | 0.590 |
Why?
|
Antineoplastic Agents | 5 | 2020 | 2351 | 0.570 |
Why?
|
Male | 43 | 2021 | 40860 | 0.570 |
Why?
|
Female | 49 | 2022 | 44405 | 0.560 |
Why?
|
Aged | 31 | 2022 | 18353 | 0.540 |
Why?
|
Patient Selection | 5 | 2014 | 685 | 0.520 |
Why?
|
Information Services | 2 | 2005 | 23 | 0.500 |
Why?
|
Patient Outcome Assessment | 1 | 2014 | 83 | 0.480 |
Why?
|
Terminal Care | 2 | 2020 | 130 | 0.460 |
Why?
|
Stress, Psychological | 2 | 2016 | 313 | 0.450 |
Why?
|
Health Care Costs | 1 | 2015 | 237 | 0.450 |
Why?
|
Internet | 2 | 2005 | 309 | 0.420 |
Why?
|
Conflict of Interest | 3 | 2007 | 67 | 0.410 |
Why?
|
Cross-Sectional Studies | 5 | 2022 | 1610 | 0.410 |
Why?
|
Health Care Surveys | 5 | 2020 | 277 | 0.400 |
Why?
|
Parents | 2 | 2012 | 269 | 0.390 |
Why?
|
Minors | 1 | 2010 | 15 | 0.380 |
Why?
|
Young Adult | 11 | 2020 | 5961 | 0.370 |
Why?
|
Aged, 80 and over | 14 | 2022 | 6481 | 0.370 |
Why?
|
Quality of Life | 9 | 2022 | 1575 | 0.360 |
Why?
|
Mutation | 4 | 2023 | 3952 | 0.350 |
Why?
|
Genetic Predisposition to Disease | 4 | 2018 | 2267 | 0.350 |
Why?
|
Oncologists | 2 | 2021 | 35 | 0.350 |
Why?
|
Adult Children | 1 | 2009 | 12 | 0.350 |
Why?
|
Adolescent | 13 | 2016 | 8968 | 0.340 |
Why?
|
Data Collection | 6 | 2008 | 371 | 0.340 |
Why?
|
United States | 10 | 2020 | 6637 | 0.330 |
Why?
|
Motivation | 6 | 2021 | 287 | 0.330 |
Why?
|
Palliative Care | 3 | 2020 | 256 | 0.330 |
Why?
|
Therapeutic Human Experimentation | 2 | 1999 | 20 | 0.320 |
Why?
|
Personal Autonomy | 5 | 2003 | 112 | 0.320 |
Why?
|
Placebos | 2 | 2008 | 218 | 0.320 |
Why?
|
Continuity of Patient Care | 1 | 2009 | 169 | 0.320 |
Why?
|
Adaptation, Psychological | 2 | 2009 | 157 | 0.300 |
Why?
|
Interviews as Topic | 4 | 2016 | 319 | 0.300 |
Why?
|
Heterozygote | 1 | 2008 | 365 | 0.300 |
Why?
|
Pediatrics | 2 | 2012 | 344 | 0.290 |
Why?
|
Anxiety | 2 | 2021 | 287 | 0.280 |
Why?
|
Academic Medical Centers | 2 | 2019 | 377 | 0.280 |
Why?
|
Hospitals, Urban | 1 | 2005 | 54 | 0.260 |
Why?
|
Volunteers | 1 | 2005 | 19 | 0.260 |
Why?
|
Educational Status | 4 | 2016 | 187 | 0.260 |
Why?
|
Empirical Research | 3 | 1999 | 19 | 0.250 |
Why?
|
Pilot Projects | 6 | 2016 | 837 | 0.240 |
Why?
|
Spirituality | 1 | 2005 | 87 | 0.240 |
Why?
|
Clinical Trials, Phase II as Topic | 2 | 2009 | 173 | 0.240 |
Why?
|
Illinois | 2 | 2020 | 461 | 0.240 |
Why?
|
Awareness | 1 | 2003 | 92 | 0.220 |
Why?
|
Biopsy | 1 | 2006 | 1160 | 0.220 |
Why?
|
Mass Media | 1 | 2002 | 26 | 0.220 |
Why?
|
Patient Education as Topic | 4 | 2017 | 351 | 0.200 |
Why?
|
Biomedical Research | 2 | 2017 | 375 | 0.200 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2023 | 755 | 0.200 |
Why?
|
Research Design | 5 | 2014 | 594 | 0.200 |
Why?
|
Breast Neoplasms | 4 | 2016 | 2881 | 0.200 |
Why?
|
Communication | 4 | 2017 | 438 | 0.200 |
Why?
|
Cancer Survivors | 1 | 2022 | 85 | 0.190 |
Why?
|
Risk Assessment | 6 | 2000 | 2253 | 0.190 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2012 | 2434 | 0.180 |
Why?
|
Patient Advocacy | 2 | 1997 | 49 | 0.180 |
Why?
|
Hospitals, University | 1 | 2020 | 193 | 0.180 |
Why?
|
Eligibility Determination | 1 | 2019 | 31 | 0.180 |
Why?
|
Child | 7 | 2014 | 6913 | 0.180 |
Why?
|
Hematopoietic Stem Cell Transplantation | 4 | 2010 | 878 | 0.180 |
Why?
|
Protein Kinase Inhibitors | 2 | 2023 | 589 | 0.180 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2020 | 106 | 0.170 |
Why?
|
Patient Care | 1 | 2020 | 100 | 0.170 |
Why?
|
Drug Evaluation | 1 | 1999 | 141 | 0.170 |
Why?
|
Research | 2 | 1999 | 253 | 0.170 |
Why?
|
Knowledge | 2 | 2017 | 29 | 0.170 |
Why?
|
Vinblastine | 1 | 1998 | 108 | 0.160 |
Why?
|
Health Literacy | 2 | 2017 | 70 | 0.160 |
Why?
|
Remission Induction | 3 | 2016 | 722 | 0.160 |
Why?
|
Leukemia, Myeloid | 2 | 2012 | 249 | 0.160 |
Why?
|
Paclitaxel | 1 | 1998 | 460 | 0.140 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 1998 | 276 | 0.140 |
Why?
|
Prospective Studies | 5 | 2021 | 4194 | 0.140 |
Why?
|
Drug Therapy | 1 | 2016 | 70 | 0.140 |
Why?
|
Vulnerable Populations | 4 | 2014 | 76 | 0.140 |
Why?
|
Family Health | 2 | 2009 | 162 | 0.140 |
Why?
|
Neuropsychological Tests | 1 | 2018 | 502 | 0.140 |
Why?
|
Internal-External Control | 1 | 2016 | 44 | 0.140 |
Why?
|
Marital Status | 1 | 2016 | 40 | 0.140 |
Why?
|
Ovarian Neoplasms | 1 | 2022 | 738 | 0.140 |
Why?
|
Religion | 1 | 2016 | 87 | 0.140 |
Why?
|
Social Class | 1 | 2016 | 127 | 0.130 |
Why?
|
Transplantation Conditioning | 3 | 2007 | 373 | 0.130 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 329 | 0.130 |
Why?
|
Persons | 3 | 1999 | 6 | 0.120 |
Why?
|
Postal Service | 2 | 2012 | 16 | 0.120 |
Why?
|
Karnofsky Performance Status | 3 | 2006 | 40 | 0.120 |
Why?
|
Cohort Studies | 5 | 2008 | 2759 | 0.120 |
Why?
|
Chicago | 2 | 2009 | 1377 | 0.110 |
Why?
|
Adolescent Health Services | 1 | 2013 | 11 | 0.110 |
Why?
|
Myelodysplastic Syndromes | 2 | 2007 | 345 | 0.110 |
Why?
|
Physicians, Family | 1 | 2013 | 40 | 0.110 |
Why?
|
Follow-Up Studies | 3 | 2018 | 3616 | 0.110 |
Why?
|
Guideline Adherence | 2 | 2014 | 222 | 0.110 |
Why?
|
Treatment Outcome | 8 | 2010 | 7949 | 0.110 |
Why?
|
Salvage Therapy | 2 | 2017 | 232 | 0.110 |
Why?
|
Depression | 1 | 2016 | 472 | 0.100 |
Why?
|
Prevalence | 1 | 2016 | 1239 | 0.100 |
Why?
|
Advance Directives | 1 | 2012 | 64 | 0.100 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 307 | 0.100 |
Why?
|
Neoplasms, Second Primary | 2 | 2012 | 252 | 0.100 |
Why?
|
Melphalan | 3 | 2007 | 97 | 0.100 |
Why?
|
Odds Ratio | 2 | 2009 | 677 | 0.100 |
Why?
|
Perception | 1 | 2012 | 167 | 0.100 |
Why?
|
Internship and Residency | 1 | 2020 | 1001 | 0.090 |
Why?
|
Severity of Illness Index | 1 | 2016 | 1796 | 0.090 |
Why?
|
Myeloid Cells | 1 | 2010 | 97 | 0.090 |
Why?
|
Transplantation, Homologous | 5 | 2012 | 996 | 0.090 |
Why?
|
Practice Guidelines as Topic | 3 | 2014 | 1030 | 0.090 |
Why?
|
Stem Cell Transplantation | 2 | 2012 | 183 | 0.080 |
Why?
|
Patient Reported Outcome Measures | 2 | 2022 | 165 | 0.080 |
Why?
|
Taiwan | 1 | 2008 | 23 | 0.080 |
Why?
|
Bone Marrow Transplantation | 2 | 2001 | 285 | 0.080 |
Why?
|
Federal Government | 2 | 1999 | 29 | 0.080 |
Why?
|
fms-Like Tyrosine Kinase 3 | 2 | 2023 | 121 | 0.080 |
Why?
|
Government Regulation | 2 | 1999 | 49 | 0.080 |
Why?
|
California | 1 | 2008 | 138 | 0.080 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2004 | 850 | 0.080 |
Why?
|
China | 1 | 2008 | 228 | 0.080 |
Why?
|
Consent Forms | 2 | 1999 | 11 | 0.080 |
Why?
|
Health Behavior | 1 | 2009 | 183 | 0.080 |
Why?
|
Herb-Drug Interactions | 1 | 2007 | 4 | 0.080 |
Why?
|
Qualitative Research | 2 | 2019 | 256 | 0.080 |
Why?
|
Plant Preparations | 1 | 2007 | 19 | 0.070 |
Why?
|
Ethics Committees, Research | 2 | 2014 | 33 | 0.070 |
Why?
|
Time Factors | 4 | 2009 | 5198 | 0.070 |
Why?
|
Medical Staff, Hospital | 1 | 2007 | 107 | 0.070 |
Why?
|
Vitamins | 1 | 2007 | 81 | 0.070 |
Why?
|
Medical Errors | 1 | 2007 | 115 | 0.070 |
Why?
|
Clinical Competence | 1 | 2012 | 750 | 0.070 |
Why?
|
Specimen Handling | 1 | 2006 | 98 | 0.070 |
Why?
|
Dietary Supplements | 1 | 2007 | 128 | 0.070 |
Why?
|
Logistic Models | 1 | 2009 | 1184 | 0.070 |
Why?
|
Pedigree | 1 | 2008 | 966 | 0.070 |
Why?
|
Age Factors | 2 | 2012 | 1842 | 0.070 |
Why?
|
Quality Control | 1 | 2005 | 117 | 0.070 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 199 | 0.060 |
Why?
|
Lymphokines | 1 | 1985 | 76 | 0.060 |
Why?
|
Problem Solving | 1 | 2005 | 54 | 0.060 |
Why?
|
Cladribine | 1 | 2004 | 35 | 0.060 |
Why?
|
CD-ROM | 1 | 2004 | 3 | 0.060 |
Why?
|
Teaching Materials | 1 | 2004 | 12 | 0.060 |
Why?
|
Risk Factors | 4 | 2006 | 5397 | 0.060 |
Why?
|
Sex Factors | 2 | 2005 | 1053 | 0.060 |
Why?
|
Third-Party Consent | 1 | 2004 | 24 | 0.060 |
Why?
|
Family Relations | 1 | 2004 | 35 | 0.060 |
Why?
|
Drug Administration Schedule | 3 | 2004 | 916 | 0.060 |
Why?
|
Life Expectancy | 1 | 2004 | 85 | 0.060 |
Why?
|
Intention | 1 | 2004 | 51 | 0.060 |
Why?
|
Metaphor | 1 | 2003 | 3 | 0.060 |
Why?
|
Child, Preschool | 1 | 2010 | 3608 | 0.060 |
Why?
|
Deoxycytidine | 1 | 2004 | 237 | 0.060 |
Why?
|
Attitude to Death | 1 | 2003 | 36 | 0.060 |
Why?
|
Refusal to Treat | 1 | 2003 | 27 | 0.060 |
Why?
|
Terminally Ill | 1 | 2003 | 23 | 0.060 |
Why?
|
Reimbursement Mechanisms | 1 | 2003 | 40 | 0.060 |
Why?
|
Ethics, Clinical | 1 | 2003 | 48 | 0.060 |
Why?
|
Bone Marrow | 1 | 1985 | 434 | 0.060 |
Why?
|
Culture | 1 | 2003 | 53 | 0.060 |
Why?
|
Electronics | 1 | 2022 | 15 | 0.060 |
Why?
|
Hematopoietic Stem Cells | 1 | 1985 | 292 | 0.060 |
Why?
|
Focus Groups | 1 | 2003 | 153 | 0.050 |
Why?
|
Demography | 1 | 2003 | 177 | 0.050 |
Why?
|
Students, Medical | 1 | 2007 | 384 | 0.050 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2002 | 59 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2005 | 392 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2003 | 297 | 0.050 |
Why?
|
Mitoxantrone | 2 | 2012 | 68 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2007 | 1305 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2004 | 751 | 0.050 |
Why?
|
Human Experimentation | 1 | 2001 | 39 | 0.050 |
Why?
|
Cytarabine | 2 | 2012 | 218 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2012 | 1680 | 0.050 |
Why?
|
Whole-Body Irradiation | 1 | 2000 | 63 | 0.050 |
Why?
|
Evaluation Studies as Topic | 1 | 2000 | 274 | 0.050 |
Why?
|
Drugs, Investigational | 1 | 2000 | 37 | 0.050 |
Why?
|
Morals | 1 | 2021 | 92 | 0.050 |
Why?
|
Etoposide | 1 | 2000 | 196 | 0.040 |
Why?
|
Professional Staff Committees | 1 | 1999 | 7 | 0.040 |
Why?
|
Researcher-Subject Relations | 1 | 1999 | 4 | 0.040 |
Why?
|
HIV Wasting Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
|
Uncertainty | 1 | 1999 | 71 | 0.040 |
Why?
|
Mental Competency | 1 | 1999 | 49 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 1999 | 169 | 0.040 |
Why?
|
Li-Fraumeni Syndrome | 1 | 2018 | 5 | 0.040 |
Why?
|
Forecasting | 1 | 1999 | 303 | 0.040 |
Why?
|
History, 20th Century | 1 | 1999 | 312 | 0.040 |
Why?
|
Control Groups | 1 | 1997 | 15 | 0.040 |
Why?
|
Paternalism | 1 | 1997 | 24 | 0.040 |
Why?
|
Recurrence | 3 | 2012 | 1137 | 0.040 |
Why?
|
Germ Cells | 1 | 2018 | 126 | 0.040 |
Why?
|
Acute Disease | 2 | 2012 | 824 | 0.040 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2001 | 369 | 0.040 |
Why?
|
Neutropenia | 2 | 2010 | 215 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2012 | 1958 | 0.040 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1997 | 78 | 0.040 |
Why?
|
Lung | 2 | 2020 | 1167 | 0.040 |
Why?
|
Testosterone | 1 | 1998 | 268 | 0.040 |
Why?
|
Therapies, Investigational | 1 | 1996 | 17 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2000 | 452 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 1997 | 127 | 0.040 |
Why?
|
Alemtuzumab | 2 | 2007 | 83 | 0.040 |
Why?
|
Thrombocytopenia | 2 | 2010 | 183 | 0.040 |
Why?
|
Antibodies, Neoplasm | 2 | 2007 | 84 | 0.040 |
Why?
|
Hodgkin Disease | 1 | 1997 | 177 | 0.040 |
Why?
|
Knee Prosthesis | 1 | 1996 | 33 | 0.040 |
Why?
|
Vidarabine | 2 | 2007 | 141 | 0.040 |
Why?
|
Gene Frequency | 1 | 2018 | 676 | 0.030 |
Why?
|
Income | 1 | 2016 | 75 | 0.030 |
Why?
|
Neoplasm Proteins | 2 | 2012 | 532 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1997 | 261 | 0.030 |
Why?
|
Survival Analysis | 2 | 2010 | 1536 | 0.030 |
Why?
|
Graft vs Host Disease | 3 | 2005 | 364 | 0.030 |
Why?
|
Urban Population | 1 | 2016 | 213 | 0.030 |
Why?
|
Pandemics | 1 | 2021 | 739 | 0.030 |
Why?
|
Cultural Diversity | 1 | 1995 | 51 | 0.030 |
Why?
|
Disease-Free Survival | 3 | 2005 | 1203 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2018 | 853 | 0.030 |
Why?
|
Social Support | 1 | 2016 | 193 | 0.030 |
Why?
|
Trust | 1 | 1995 | 95 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 450 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2006 | 857 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 1056 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2016 | 1015 | 0.030 |
Why?
|
Physician's Role | 1 | 1994 | 179 | 0.030 |
Why?
|
Canada | 1 | 2013 | 204 | 0.030 |
Why?
|
Physicians, Primary Care | 1 | 2014 | 104 | 0.030 |
Why?
|
Age of Onset | 1 | 2013 | 306 | 0.030 |
Why?
|
Hematologic Diseases | 1 | 2012 | 79 | 0.030 |
Why?
|
Japan | 1 | 2012 | 307 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2016 | 554 | 0.030 |
Why?
|
Diarrhea | 1 | 2012 | 181 | 0.020 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2007 | 929 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2012 | 386 | 0.020 |
Why?
|
Risk | 1 | 2012 | 673 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2007 | 1376 | 0.020 |
Why?
|
Internal Medicine | 1 | 2014 | 347 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 859 | 0.020 |
Why?
|
Pamphlets | 1 | 2009 | 14 | 0.020 |
Why?
|
Computer-Assisted Instruction | 1 | 2009 | 43 | 0.020 |
Why?
|
Ethics, Research | 1 | 2009 | 52 | 0.020 |
Why?
|
Social Perception | 1 | 2009 | 95 | 0.020 |
Why?
|
Societies, Medical | 1 | 2012 | 572 | 0.020 |
Why?
|
Organizational Culture | 1 | 2007 | 33 | 0.020 |
Why?
|
Self Efficacy | 1 | 2007 | 53 | 0.020 |
Why?
|
Safety Management | 1 | 2007 | 56 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2007 | 115 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2007 | 220 | 0.020 |
Why?
|
Leukemia, Experimental | 1 | 1985 | 15 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 1985 | 40 | 0.020 |
Why?
|
Interleukin-3 | 1 | 1985 | 36 | 0.020 |
Why?
|
Karyotyping | 1 | 1985 | 250 | 0.020 |
Why?
|
Antigens, Viral | 1 | 1985 | 143 | 0.020 |
Why?
|
Retroviridae | 1 | 1985 | 78 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 1986 | 143 | 0.020 |
Why?
|
Receptors, Immunologic | 1 | 1985 | 135 | 0.020 |
Why?
|
Lymphoma | 1 | 1986 | 262 | 0.020 |
Why?
|
Fatigue | 1 | 2004 | 174 | 0.010 |
Why?
|
Leukemia | 1 | 1986 | 318 | 0.010 |
Why?
|
Cell Line | 2 | 1986 | 2466 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2016 | 2260 | 0.010 |
Why?
|
Cell Survival | 1 | 1986 | 966 | 0.010 |
Why?
|
Comorbidity | 1 | 2006 | 943 | 0.010 |
Why?
|
Survival Rate | 1 | 2006 | 1856 | 0.010 |
Why?
|
Cytogenetic Analysis | 1 | 2001 | 71 | 0.010 |
Why?
|
Mood Disorders | 1 | 2001 | 81 | 0.010 |
Why?
|
Methotrexate | 1 | 2001 | 249 | 0.010 |
Why?
|
Survival | 1 | 2000 | 21 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2001 | 299 | 0.010 |
Why?
|
Stomatitis | 1 | 2000 | 30 | 0.010 |
Why?
|
Mouth Mucosa | 1 | 2000 | 66 | 0.010 |
Why?
|
Cause of Death | 1 | 2001 | 277 | 0.010 |
Why?
|
Blood Platelets | 1 | 2000 | 149 | 0.010 |
Why?
|
Cells, Cultured | 1 | 1985 | 2810 | 0.010 |
Why?
|
Menstruation | 1 | 1998 | 30 | 0.010 |
Why?
|
Administration, Cutaneous | 1 | 1998 | 58 | 0.010 |
Why?
|
Neutrophils | 1 | 2000 | 306 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2012 | 8431 | 0.010 |
Why?
|
Nutritional Status | 1 | 1998 | 83 | 0.010 |
Why?
|
Body Composition | 1 | 1998 | 68 | 0.010 |
Why?
|
Lung Diseases | 1 | 2000 | 263 | 0.010 |
Why?
|
Weight Gain | 1 | 1998 | 123 | 0.010 |
Why?
|
Herpes Zoster | 1 | 1997 | 78 | 0.010 |
Why?
|
Role | 1 | 1996 | 11 | 0.010 |
Why?
|
Graft Survival | 1 | 2000 | 883 | 0.010 |
Why?
|
Osteoarthritis | 1 | 1996 | 73 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 1996 | 202 | 0.010 |
Why?
|
Knee Joint | 1 | 1996 | 168 | 0.010 |
Why?
|
Interpersonal Relations | 1 | 1996 | 170 | 0.010 |
Why?
|
Regression Analysis | 1 | 1996 | 595 | 0.010 |
Why?
|
Liver | 1 | 2000 | 1229 | 0.010 |
Why?
|
Mice | 2 | 1986 | 11313 | 0.010 |
Why?
|
Pain | 1 | 1996 | 389 | 0.010 |
Why?
|
Body Mass Index | 1 | 1996 | 770 | 0.010 |
Why?
|
Emotions | 1 | 1996 | 340 | 0.010 |
Why?
|
Heart Failure | 1 | 2000 | 1196 | 0.010 |
Why?
|
Animals | 2 | 1986 | 26518 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1986 | 188 | 0.000 |
Why?
|
Rats | 1 | 1986 | 3984 | 0.000 |
Why?
|